Dermatologisches zentrum buxtehude biography

Since 1996.
These 'real-life' data clearly demonstrate the substantial disease burden.
Elbekliniken Buxtehude, Skin Cancer Center.

•

Background

Treatment with programmed cell death protein (PD-1) blocking antibodies substantially improves prognosis of melanoma patients. However, there is still limited evidence how baseline demographics influence treatment efficacy in real world practice.

Methods

This registry-based observational study evaluated the therapy outcome of 1046 melanoma patients who were treated with single agent PD-1 inhibitors in the advanced setting. Demographic and baseline variables were analysed in respect to differences in overall survival (OS), time to next treatment after PD-1 inhibitor treatment (TTNT) and other outcome variables.

Results

For melanoma-specific OS, many factors were not significantly relevant. However, among the statistically significant factors (age, ECOG, LDH, line of treatment and AJCC stages M1c and M1d) the age effect was of particular interest. When grouping patients into three age groups (80) there was a higher risk of melanoma related death for patients aged 70-80 years (multivariable HR (95% CI): 1.51 (1.02-2.2)) and patients older than 80 years (multivariable

•

DRKS-ID:: DRKS00014063
Recruitment Status:: Recruiting ongoing
Date of registration in DRKS:: 2018-03-07
Last update in DRKS:: 2018-03-07
Registration type:: Retrospective

Acronym/abbreviation of the study

PD-Next

URL of the study

No Entry

Brief summary in lay language

A national, ambispective, observational multicentric case registry study in patients with advanced metastatic or non-resectable melanoma. Primary objective of this registry study is the collection of clinically important data on therapeutic efficacy of Ipilimimab and other therapies following failed PD-1 antibody therapy with Nivolumab or Pembrolizumab. Therefore data will be collected about treatment and follow-up according to routine local clinical practice up to 24 months after consent of patient.

Brief summary in scientific language

Aim: Within this ambispective, observational, multicenter case registry study 130 patients diagnosed with advanced melanoma (histologically confirmed Stage III [unresectable] or Stage IV skin, ocular, or mucosal melanoma) and whose physician has alre

•

Abstract

Background: The TREATgermany registry collects data from children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) in Germany. For this purpose, clinical and patient-reported outcomes, the course of the disease, and applied therapies are observed. Methods: TREATgermany recruits patients with moderate-to-severe AD according to the diagnostic criteria of the UK Working Party, an “Objective Scoring for Atopic Dermatitis” (oSCORAD) > 20 and/or currently antiinflammatory systemic treatment for AD or previous anti-inflammatory systemic treatment for AD within past 24 months before inclusion. No study related interventions will be performed. Currently, 59 dermatological practices, clinics, and university hospitals are participating in TREATgermany (as of May 2021). Based on the interim analysis of October 13, 2020, patient characteristics were described from 4,373 documented visits of adult participants (n = 1,025). Results: The mean age at inclusion in TREATgermany was 42 years, 57.7% of patients were men (n = 591) and 42.3% were women (n = 434). Acco